NCT06331559 2026-02-09
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Terminated
Clinical Trials
13 trialsNCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT00777582 2026-01-13
Phase I Comparative Bioavailability Study
AstraZeneca
Phase 1 Active not recruiting
NCT05240898 2025-12-18
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT06130254 2025-10-14
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06686745 2025-01-07
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT00782574 2023-12-21
Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
AstraZeneca
Phase 1 Completed
NCT04375267 2023-11-14
LuPARP
Vastra Gotaland Region
Phase 1 Unknown
NCT02588105 2022-09-19
AToM
AstraZeneca
Phase 1 Completed
NCT00819221 2022-08-30
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
AstraZeneca
Phase 1 Terminated
NCT03057145 2021-09-02
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02430311 2019-07-31
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
AstraZeneca
Phase 1 Completed
NCT00516438 2010-12-08
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
AstraZeneca
Phase 1 Completed